601607 Shanghai Pharmaceuticals Holding
- 21.15
- +1.25+6.28%
Shanghai Pharmaceuticals Holding News
Shanghai Pharmaceutical: An indicative announcement by Shanghai Pharmaceutical Group Co., Ltd. on granting a third exercise period for stock options for the first time in the 2019 A-share stock option incentive plan and limiting the exercise period for the second period of reserved stock options
An indicative announcement by Shanghai Pharmaceutical Group Co., Ltd. on granting a third exercise period for stock options for the first time in the 2019 A-share stock option incentive plan and limiting the exercise period for the second period of reserved stock options
Shanghai Pharmaceutical Group Co., Ltd. 2024 Semi-Annual Equity Distribution Implementation Notice
Announcement of Shanghai Pharmaceutical Group Co., Ltd. on the controlling shareholder\'s increase in the company\'s H shares
Announcement of Shanghai Pharmaceutical Group Co., Ltd. on the completion of the controlling shareholder\'s H share increase plan
An indicative announcement by Shanghai Pharmaceutical Group Co., Ltd. on granting a third exercise period for stock options for the first time in the 2019 A-share stock option incentive plan and limiting the exercise period for the second period of reserved stock options
sh pharma group co., ltd. announcement of the profit distribution plan for the first half of 2024
Sh Pharma's Prompt Announcement Regarding the Third Exercise Period of the First Grant of Stock Options under the 2019 A-share Stock Option Incentive Plan and Restrictions on the Second Exercise Period of Reserved Stock Options
Announcement of the Implementation of Equity Distribution for the Year 2023 by SH Pharma Group Co., Ltd.
Sh Pharma's Prompt Announcement Regarding the Third Exercise Period of the First Grant of Stock Options under the 2019 A-share Stock Option Incentive Plan and Restrictions on the Second Exercise Period of Reserved Stock Options
Announcement on the results of the third exercise period of the 2019 A-share stock option incentive plan and the second reserved exercise period of stock options for the second quarter of 2024 granted for the first time by Shanghai Pharmaceuticals Group Co., Ltd.
Announcement of Shanghai Pharmaceutical Group Co., Ltd. on the results of the 2019 A-share Stock Options Incentive Plan for the first time granting the third exercise period of stock options and the second exercise period of reserved stock options for the
Announcement of the 2023 Annual Profit Distribution Plan of Shanghai Pharmaceutical Group Co., Ltd.
Announcement of Shanghai Pharmaceutical Group Co., Ltd. on cancellation of the second exercise period of stock options granted to the company in the 2019 A-share stock option incentive plan for the first time and stock options that have expired and have no
An indicative announcement by Shanghai Pharmaceutical Group Co., Ltd. on granting a third exercise period for stock options for the first time in the 2019 A-share stock option incentive plan and limiting the exercise period for the second period of reserve
Announcement of Shanghai Pharmaceutical Group Co., Ltd. on receiving directors' proposals for the 2023 profit distribution plan and the “Improve Quality, Increase Efficiency, and Value Return” action plan
Announcement of Shanghai Pharmaceutical Group Co., Ltd. on the results of the 2019 A-share Stock Options Incentive Plan granting a second exercise period for stock options for the first time and autonomous exercise of reserved stock options for the first t
An indicative announcement by Shanghai Pharmaceutical Group Co., Ltd. on granting a third exercise period for stock options for the first time in the 2019 A-share stock option incentive plan and limiting the exercise period for the second period of reserve
An indicative announcement by Shanghai Pharmaceutical Group Co., Ltd. on the 2019 A-share Stock Options Incentive Plan for the first time granting a third exercise period for stock options and adopting an autonomous exercise model for the second period of
Legal Opinion of Mr. Guo Hao (Shanghai) Firm on matters relating to Shanghai Pharmaceutical Group Co., Ltd. adjusting the list of incentive recipients in the 2019 Stock Option Incentive Plan, granting the number of options, and canceling some options and f
Analysis
Price Target
No Data
No Data